COVID-19 in 2022—The Beginning of the End or the End of the Beginning?

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

(2022) Emma K. Accorsi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

COVID-19 Therapeutics for Nonhospitalized Patients

(2022) Rajesh T. Gandhi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021

(2022) Kristin L. Andrejko et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel

(2022) Yinon M. Bar-On et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine

(2022) Ria Lassaunière et al.   JAMA Network Open

Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-CoV-2 variants

(2021) Veronika Tchesnokova et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Winter of Omicron—The Evolving COVID-19 Pandemic

(2021) Carlos del Rio et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION